Cytochrome P450 family 3 subfamily A member 4 mRNA (CYP3A4 mRNA)

Cytochrome P450 family 3 subfamily A member 4 (CYP3A4) mRNA is the transcript responsible for the synthesis of the most significant drug-metabolizing enzyme in the human liver and gastrointestinal tract (Zanger & Schwab, 2013). This mRNA is a central regulator of the pharmacokinetics of over 50% of marketed drugs, including macrolide antibiotics, benzodiazepines, and many anticancer agents (Burk & Wojnowski, 2004). The levels of CYP3A4 mRNA are highly dynamic and are regulated by xenobiotic-sensing nuclear receptors such as the Pregnane X Receptor (PXR), which induces transcription upon binding to drugs like rifampin (NCBI Gene ID: 1576). While the protein is the traditional focus of pharmacology, the mRNA itself is a target for gene-silencing technologies like siRNA and antisense oligonucleotides (ASOs) used to study metabolic pathways or potentially modulate drug clearance (UniProt P08684). Variations in mRNA expression, driven by genetic polymorphisms or environmental induction, are a major cause of inter-individual variability in drug response and the occurrence of adverse drug reactions. In clinical practice, monitoring or modulating CYP3A4 mRNA levels is essential for predicting and managing complex drug-drug interactions. However, targeting CYP3A4 mRNA presents significant safety risks, as any substantial alteration in its levels can lead to profound drug-drug interactions, potentially causing systemic toxicity or therapeutic failure of co-administered medications.

Other names

Cytochrome P450 3A4 mRNACYP3A4 transcriptNifedipine oxidase mRNACYP3A3 mRNA

Transcriptional induction via nuclear receptors (PXR, CAR, GR) and targeted degradation via RNA interference (RNAi) or antisense oligonucleotides.